Page last updated: 2024-12-06

doqualast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

doqualast: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68830
CHEMBL ID172498
SCHEMBL ID124450
MeSH IDM0146065

Synonyms (24)

Synonym
doqualast [inn]
brn 0750153
11-oxo-11h-pyrido(2,1-b)quinazoline-2-carboxylic acid
docualast [spanish]
11-oxo-11h-pyrido(2,1-b)quinazolone-2-carboxylic acid
sm 857se
sm 857 se
11h-pyrido(2,1-b)quinazolone-2-carboxylic acid, 11-oxo-
doqualastum [latin]
doqualast
sm 857
11-oxopyrido[2,1-b]quinazoline-2-carboxylic acid
64019-03-0
CHEMBL172498
docualast
n8f510m76f ,
doqualastum
unii-n8f510m76f
AKOS022660884
SCHEMBL124450
DTXSID80214002
1,2,3,4-tetrahydro-quinoline-7-carboxylic acidmet
mfcd00864628
Q27284702

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Two additional studies were done in rats dosed with 400 mg/kg, and with 90, 200, or 400 mg/kg, respectively."( Teratogenicity of the antiallergic Sm 857 SE in rats versus rabbits.
Kast, A; Kobayashi, S; Nishimura, M; Tsunenari, Y, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID193934% inhibition of antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test after giving intraperitoneal dose of 16 mg/kg; Not significant1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Pyrido[2,1-b]quinazolinecarboxylic acids as orally active antiallergy agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (93.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (13.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]